MacroGenics

• NCT05848011

  Phase 2, Completed, 154 people, 8 May 2023

• NCT02152956

  Phase 1/2, Terminated, 244 people, 2 Jun 2014

• Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis

  Grants or research support, 20 Aug 2026

• Association of sodium-glucose co-transport protein 2 inhibitor use with clinical outcomes in patients receiving immune checkpoint inhibitors: a pan-tumor propensity-matched analysis

  Grants or research support, 6 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov